Neogen Corporation (NEOG) has demonstrated strong performance with shares rising 102.8% over the past year, outperforming the industry. The company's Food Safety division achieved its highest quarterly core growth rate since fiscal 2023 at 5.8%, while planning a 50% increase in fiscal 2027 R&D spending focused on innovation and pathogen detection. However, the company faces headwinds from foreign currency exposure affecting 51.2% of revenues and intense competition from larger corporations.

Illumina (ILMN) raised its 2026 revenue and EPS guidance following a 9.5% year-over-year revenue increase in Q2, driven by strong oncology clinical growth and expanded multiomics offerings. However, the company faces margin pressure from tariffs, freight costs, and memory inflation, with adjusted gross margin declining 120 basis points year-over-year despite manageable leverage and sufficient liquidity.

Teleflex (TFX), a Zacks Rank #2 (Buy) stock, benefits from strong growth in its Vascular business driven by central access demand, hemostatic products, and FDA approval of EZPLAZ. The Interventional platform is expanding through the BIOTRONIK acquisition with promising clinical development of Freesolve. However, foreign exchange sensitivity remains a key concern. The company has improved balance sheet flexibility with net leverage declining to 1.9X following strategic divestitures.

Healthcare companies are advancing precision medicine through gene therapy, AI diagnostics, and innovative treatments targeting age-related conditions, with several firms making significant breakthroughs in areas like longevity biotechnology and personalized care.

The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.

Veracyte is considering selling or shutting down its French subsidiary, which generates $4 million in revenue but incurs $7 million in fixed costs, leading to a $5 million loss. An analyst believes this could be a long-term positive for the company.

Insulet's Omnipod 5 has received FDA approval for type 2 diabetes patients, expanding its market potential. However, economic uncertainty and competitive pressures remain concerns for the company.

Globus Medical is gaining market share in the musculoskeletal solutions space, driven by strong performance of its products. However, the company is facing challenges from global economic factors, including rising costs and inflation.

Jens Holstein, a director at Veracyte Inc, sold 5,000 shares of the company's stock. The transaction suggests a neutral sentiment, as insider sales can be driven by various factors, including personal financial needs, rather than a negative outlook on the company's prospects.

Deteriorating geopolitical situation and supply bottlenecks mar the prospects of the Zacks Medical Instruments industry. Yet, HOLX, MASI and VCYT are worth buying based on strategic developments and fundamentals.

Veracyte, Steelcase and Applied Industrial have been highlighted in this Screen of The Week article.

Invest in companies like Veracyte (VCYT), Steelcase (SCS) and Applied Industrial Technologies (AIT), as they boast higher efficiency levels.